Drug intelligence / Profile preview

Xiaoao-Jiedu prescription

Development stage: Unknown
Lead developer: Taizhou Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Xiaoao-Jiedu prescription is a traditional Chinese medicine (TCM) formula developed by the Taizhou Hospital of Traditional Chinese Medicine. It is primarily investigated as an adjuvant therapy for advanced non-small cell lung cancer (NSCLC). The prescription is hypothesized to enhance the efficacy of immune checkpoint inhibitors, specifically PD-1 monoclonal antibodies, by modulating the tumor microenvironment. Its mechanism of action is thought to involve the sensitization of macrophages, potentially shifting them from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, thereby overcoming resistance to immunotherapy and chemotherapy.

Other names: Xiaoao Jiedu FangXiaoao-Jiedu decoction

Beyond the preview

Go deeper on Xiaoao-Jiedu prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiaoao-Jiedu prescription.

Explore the full profile